Mercurius Health equips Robert Janker Klinik with integrated oncology solutions from Philips and Elekta
10 Maggio 2023 - 10:00AM
Mercurius Health equips Robert Janker Klinik with integrated
oncology solutions from Philips and Elekta
May 10, 2023
The hospital will be equipped with state-of-the-art diagnostic
and therapeutic oncology solutions over the next three years,
contributing to enhanced patient care
Amsterdam, the Netherlands, Stockholm, Sweden, and
Madrid, Spain – Royal Philips (NYSE: PHG, AEX: PHIA), a
global leader in health technology, radiation therapy leader Elekta
(EKTA-B.ST), and oncology service provider Mercurius Health today
announced the signing of a 3-year agreement under which Philips and
Elekta will install state-of-the-art diagnostic and therapeutic
oncology equipment and associated informatics solutions at
Mercurius Health’s newly-acquired Robert Janker Klinik cancer
center in Bonn, Germany. The investment in Philips and Elekta
solutions by Mercurius Health is part of its commitment to
establishing a major presence in Germany, following the company’s
acquisition of Robert Janker Klinik earlier this year.
The agreement has been enabled by the strategic partnership
between Philips and Elekta to advance comprehensive personalized
cancer care through the deployment of precision oncology solutions.
The Robert Janker Klinik, a specialized hospital in oncology and
palliative care, focuses on minimally invasive diagnostics and
treatments for cancer. The hospital has three inpatient departments
(radiology, radiotherapy and palliative care) and an outpatient
unit for radiotherapy. It employs around 130 staff and treats
patients from across the region as well as national and
international patients.
“This major investment in cutting-edge technology by Mercurius
Health means many of the projects currently in planning can be
rapidly moved forward, making us a showcase for what the future of
cancer care will look like,” said Prof. Dr. Attila Kovács, Head
Physician of the Clinic for Diagnostic and Interventional Radiology
and Neuroradiology.
“The combination of Philips’ diagnostic imaging and oncology
informatics solutions, and Elekta’s radiation therapy solutions
means we will be able to offer our patients state-of-the-art
therapy for tumors such as prostate and liver cancer that are
currently difficult to treat, improving clinical outcomes,” said
Prof. Dr. Michael Pinkawa, Radiation Oncologist and Head of
Radiotherapy at Robert Janker Klinik.
Bringing data and actionable insights to the benefit of
cancer patientsTo make a precise and informed diagnosis
and select the optimal therapy for each individual cancer patient,
oncologists often need to consider and scrutinize around 10,000
data points, many of which reside in disparate IT systems –
electronic medical records, lab systems, radiology, pathology, and
genomics. Philips and Elekta bring all this data together and
translate it into actionable insights, and pathways with
predictable outcomes for each patient [1].
The combined solutions enable oncologists to deliver precise and
personalized therapies that treat tumors effectively while sparing
adjacent tissue and organs at risk. Installed in Robert Janker
Klinik, they will provide Mercurius Health with a platform to
showcase its consultancy and B2B oncology services in the German
market and continue its pioneering work in increasing productivity,
improving patient and staff experience, and enhancing clinical
care.
[1] Results from case studies are not predictive of results in
other cases. Results in other cases may vary.
For further information, please contact:
Mark GrovesPhilips Global Press OfficeTel: +31 631 639
916E-mail: mark.groves@philips.com
Mattias ThorssonVice President, Head of Corporate
Communications, Elekta Tel: +46 70 865
8012E-mail: mattias.thorsson@elekta.com
Laura Terzagui FernándezDirector of Marketing &
Communications, Mercurius HealthTel: +34 650 446
543E-mail: laura.terzagui@mercuriushealth.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being through meaningful innovation. Philips’ patient- and
people-centric innovation leverages advanced technology and deep
clinical and consumer insights to deliver personal health solutions
for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, ultrasound, image-guided therapy, monitoring
and enterprise informatics, as well as in personal health. Philips
generated 2022 sales of EUR 17.8 billion and employs approximately
77,000 employees with sales and services in more than 100
countries. News about Philips can be found at
www.philips.com/newscenter.
About ElektaAs a leader in precision radiation
therapy, Elekta is committed to ensuring every patient has access
to the best cancer care possible. We openly collaborate with
customers to advance sustainable, outcome-driven and cost-efficient
solutions to meet evolving patient needs, improve lives and bring
hope to everyone dealing with cancer. To us, it's personal, and our
global team of 4,700 employees combine passion, science, and
imagination to profoundly change cancer care. We don’t just build
technology, we build hope. Elekta is headquartered in Stockholm,
Sweden, with offices in more than 40 countries and listed on Nasdaq
Stockholm. For more information, visit elekta.com or follow @Elekta
on Twitter.
About Mercurius HealthMercurius Health is the
European leader of B2B services to hospitals and oncology centers
with specializations in radiotherapy, nuclear medicine and
radiology. Services include advisory, remote planning,
commissioning, training & education, outsourced operations and
financing of equipment used in centers and are mostly provided in
Europe and Africa. www.mercuriushealth.com
- Clinicians looking at screen
Grafico Azioni Koninklijke Philips NV (BIT:PHIA)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Koninklijke Philips NV (BIT:PHIA)
Storico
Da Ott 2023 a Ott 2024